Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.42 USD | -0.27% | -5.24% | -26.75% |
Financials (USD)
Sales 2024 * | 34.3M | Sales 2025 * | 24.82M | Capitalization | 591M |
---|---|---|---|---|---|
Net income 2024 * | -206M | Net income 2025 * | -242M | EV / Sales 2024 * | 9.88 x |
Net cash position 2024 * | 252M | Net cash position 2025 * | 95M | EV / Sales 2025 * | 20 x |
P/E ratio 2024 * |
-3.02
x | P/E ratio 2025 * |
-2.9
x | Employees | 265 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.09% |
Latest transcript on Editas Medicine, Inc.
1 day | -0.27% | ||
1 week | -5.24% | ||
Current month | -26.24% | ||
1 month | -32.97% | ||
3 months | -28.31% | ||
6 months | +7.23% | ||
Current year | -26.75% |
Managers | Title | Age | Since |
---|---|---|---|
Gilmore O’Neill
CEO | Chief Executive Officer | 59 | 22-05-31 |
Erick Lucera
DFI | Director of Finance/CFO | 57 | 23-05-16 |
Linda Burkly
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Emma Reeve
CHM | Chairman | 63 | 21-09-02 |
David Scadden
BRD | Director/Board Member | 71 | 19-02-05 |
Akshay Vaishnaw
BRD | Director/Board Member | 61 | 16-07-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.83% | 2 M€ | -25.75% | ||
0.13% | 2 M€ | -.--% | ||
0.09% | 0 M€ | 0.00% | - | |
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 7.42 | -0.27% | 1,561,233 |
24-03-27 | 7.44 | +3.05% | 1,281,507 |
24-03-26 | 7.22 | -1.90% | 1,850,850 |
24-03-25 | 7.36 | -1.47% | 1,171,132 |
24-03-22 | 7.47 | -4.60% | 1,267,855 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.75% | 591M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |